Your institution may have access to this item. Find your institution then sign in to continue.
Title
Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression.
Abstract
The article focuses on comparing the efficacy of esketamine nasal spray with extended-release quetiapine in inducing remission in patients with treatment-resistant depression. Topics discussed include the trial methodology, treatment outcomes at eight and 32 weeks, and the occurrence of serious adverse events associated with each treatment.